Physician profile
Patrick Reilly
NPI 1346651692
$4,322.19
in general payments reported to CMS, 2019-2025
33 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $402 · 2021: $616 · 2022: $672 · 2023: $815 · 2024: $917 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.60 | 2021-2025 | |
| Lilly USA, LLC | $403.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $379.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $288.81 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $276.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $239.13 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.72 | 2020-2025 | Jardiance, Spiriva Respimat, Tradjenta |
| Pfizer INC. | $197.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $139.54 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $138.04 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.99 | 2023-2025 | |
| Amgen INC. | $107.10 | 2019-2024 | Otezla, Repatha |
| Daiichi Sankyo INC. | $92.08 | 2019-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $75.79 | 2021-2024 | |
| Esperion Therapeutics, INC. | $63.61 | 2020-2023 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $62.72 | 2025 | Auvelity |
| Dexcom, INC. | $59.44 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $43.87 | 2023-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $42.78 | 2020 | |
| Exact Sciences Corporation | $41.46 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $40.67 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $29.50 | 2019-2023 | |
| Allergan, INC. | $27.98 | 2020 | |
| Idorsia Pharmaceuticals US INC | $27.36 | 2023-2024 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $26.52 | 2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $24.81 | 2021 | |
| Corcept Therapeutics | $24.47 | 2025 | Korlym |
| Nestle Healthcare Nutrition INC. | $19.42 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.28 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $14.43 | 2020 | |
| Shire North American Group INC | $13.52 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.51 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.